UnknownPhase 4NCT05353192

A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia

Studying Achondroplasia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Changchun GeneScience Pharmaceutical Co., Ltd.
Principal Investigator
Feihong Luo
Children's Hospital of Fudan University
Intervention
Recombinant human growth hormone(drug)
Enrollment
38 enrolled
Eligibility
2-10 years · All sexes
Timeline
2022 – 2025

Study locations (1)

Collaborators

Children's Hospital of Fudan University · Tongji Hospital · Children's Hospital of Nanjing Medical University · Jiangxi Province Children's Hospital · Chengdu Women's and Children's Central Hospital · Shandong Provincial Hospital · Shengjing Hospital · Shanghai Children's Hospital · Children's Hospital of The Capital Institute of Pediatrics · West China Second University Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05353192 on ClinicalTrials.gov

Other trials for Achondroplasia

Additional recruiting or active studies for the same condition.

See all trials for Achondroplasia →

← Back to all trials